Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Severe Takayasu Patients
NCT07477795Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of secukinumab in Takayasu arteritis (TAK), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT07477795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477795.